ZOMETA® Renal Cell Carcinoma Case Study | ZOMETA Can Delay Time To First Pathologic Fracture
Home

Videos
View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

 
European Summary of Product Characteristics
For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics 		 
ZOMETA Patient Case Study: Renal Cell Carcinoma ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

ZOMETA® Renal Cell Carcinoma Patient Case Study – Carlo Carlo V.
  • Aged 67 years
  • Retired accountant
  • Takes sculpting classes twice a week
Medical Profile The clinical question Reasons for ZOMETA How to use ZOMETA References
Page  1 2 3

ZOMETA® can delay time to first pathologic fracture in patients like Carlo with advanced renal cell carcinoma

Time to first pathologic fracture5
Time to first pathologic fracture graph

  • ZOMETA significantly extended median time to first pathologic fracture vs placebo (median not reached vs 168 days, P=.003)

Page  1 2 3


 

Disclaimer: This is an international website for ZOMETA® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US flag at the top right corner of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

About ZOMETA | ZOMETA Patient Case Studies | ZOMETA Dosing & Administration | ZOMETA Safety & Tolerability | ZOMETA Clinical News | ZOMETA For Your Patients | Professional Resource Center
ZOMETA Around the World

About Novartis OncologySiteMapContactPrivacy
 


Use of this website is subject to our Terms of Use
© 2010 Novartis AG.